Key Points
- Director Frank Morich bought 15,000 Perspective Therapeutics shares at $1 each, a $15,000 purchase disclosed in an SEC filing.
- The company missed quarterly expectations, reporting a loss of $0.27 per share versus a $0.24 consensus loss, and revenue of $0.02 million versus $0.06 million expected. Shares opened at $0.92 and were down 2%.
- Analysts maintain a Moderate Buy consensus, with an average price target of $10.10; some firms recently lowered their individual targets.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) Director Frank Morich bought 15,000 shares of the company's stock in a transaction on Thursday, November 12th. The stock was purchased at an average price of $1.00 per share, with a total value of $15,000.00. Following the completion of the transaction, the director directly owned 15,000 shares of the company's stock, valued at approximately $15,000. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Perspective Therapeutics Stock Down 2.0%
NYSEAMERICAN:CATX opened at $0.92 on Tuesday. The firm's 50 day simple moving average is $2.06 and its 200 day simple moving average is $3.43. The company has a current ratio of 5.18, a quick ratio of 6.61 and a debt-to-equity ratio of 0.01. Perspective Therapeutics, Inc. has a one year low of $0.78 and a one year high of $6.16.
Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. On average, equities analysts anticipate that Perspective Therapeutics, Inc. will post -1.01 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the stock. Wedbush reaffirmed an "outperform" rating and set a $7.00 price target (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday, November 10th. BMO Capital Markets reiterated an "outperform" rating on shares of Perspective Therapeutics in a research report on Friday, October 30th. Piper Sandler cut their price target on Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating on the stock in a report on Tuesday, August 11th. BTIG Research reiterated a "buy" rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Finally, Bank of America decreased their price target on Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $10.10.
Check Out Our Latest Stock Report on Perspective Therapeutics
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Provenance Wealth Advisors LLC purchased a new position in shares of Perspective Therapeutics in the third quarter worth about $44,000. Auctus Advisors LLC lifted its stake in shares of Perspective Therapeutics by 83.6% during the 3rd quarter. Auctus Advisors LLC now owns 37,359 shares of the company's stock valued at $103,000 after buying an additional 17,015 shares in the last quarter. Taylor & Morgan Wealth Management LLC boosted its holdings in shares of Perspective Therapeutics by 30.3% in the third quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company's stock worth $236,000 after acquiring an additional 20,000 shares during the period. Russell Investments Group Ltd. boosted its stake in Perspective Therapeutics by 53.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company's stock worth $168,000 after purchasing an additional 21,150 shares during the period. Finally, Quantinno Capital Management LP purchased a new position in Perspective Therapeutics during the first quarter valued at approximately $273,000. Institutional investors own 54.66% of the company's stock.
About Perspective Therapeutics
(
Get Free Report)
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company's investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].